Literature DB >> 16155573

Lipopolysaccharide deacylation by an endogenous lipase controls innate antibody responses to Gram-negative bacteria.

Mingfang Lu1, Mei Zhang, Akira Takashima, Jerrold Weiss, Michael A Apicella, Xiang-Hong Li, Dorothy Yuan, Robert S Munford.   

Abstract

T cell-independent type 1 agonists such as Gram-negative bacterial lipopolysaccharides can stimulate B lymphocytes to proliferate and produce antibodies by signaling through Toll-like receptors. This phenomenon is well established in vitro, yet polyclonal B cell responses after bacterial infection in vivo are often weak and short-lived. We show here that B cell proliferation and polyclonal antibody production in response to Gram-negative bacterial infection are modulated by acyloxyacyl hydrolase, a host enzyme that deacylates bacterial lipopolysaccharides. Deacylation of lipopolysaccharide occurred over several days, allowing lipopolysaccharide to act as an innate immune stimulant yet limiting the eventual amount of B cell proliferation and polyclonal antibody production. Control of lipopolysaccharide activation by acyloxyacyl hydrolase indicates that mammals can regulate immune responses to bacterial infection by chemical modification of a Toll-like receptor agonist.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16155573     DOI: 10.1038/ni1246

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  32 in total

Review 1.  Biochemical transformation of bacterial lipopolysaccharides by acyloxyacyl hydrolase reduces host injury and promotes recovery.

Authors:  Robert S Munford; Jerrold P Weiss; Mingfang Lu
Journal:  J Biol Chem       Date:  2020-12-18       Impact factor: 5.157

Review 2.  The bactericidal/permeability-increasing protein (BPI) in infection and inflammatory disease.

Authors:  Hendrik Schultz; Jerrold P Weiss
Journal:  Clin Chim Acta       Date:  2007-07-13       Impact factor: 3.786

Review 3.  Sensing gram-negative bacterial lipopolysaccharides: a human disease determinant?

Authors:  Robert S Munford
Journal:  Infect Immun       Date:  2007-12-17       Impact factor: 3.441

4.  ABCA1 promotes the efflux of bacterial LPS from macrophages and accelerates recovery from LPS-induced tolerance.

Authors:  Patricia A Thompson; Karine C Gauthier; Alan W Varley; Richard L Kitchens
Journal:  J Lipid Res       Date:  2010-05-15       Impact factor: 5.922

Review 5.  The metabolic serine hydrolases and their functions in mammalian physiology and disease.

Authors:  Jonathan Z Long; Benjamin F Cravatt
Journal:  Chem Rev       Date:  2011-06-23       Impact factor: 60.622

6.  Fine mapping study reveals novel candidate genes for carotid intima-media thickness in Dominican Republican families.

Authors:  Liyong Wang; Ashley Beecham; Degen Zhuo; Chuanhui Dong; Susan H Blanton; Tatjana Rundek; Ralph L Sacco
Journal:  Circ Cardiovasc Genet       Date:  2012-03-14

7.  Hepatic uptake and deacylation of the LPS in bloodborne LPS-lipoprotein complexes.

Authors:  Baomei Shao; Robert S Munford; Richard Kitchens; Alan W Varley
Journal:  Innate Immun       Date:  2012-03-22       Impact factor: 2.680

8.  Lipooligosaccharide Structures of Invasive and Carrier Isolates of Neisseria meningitidis Are Correlated with Pathogenicity and Carriage.

Authors:  Constance M John; Nancy J Phillips; Richard Din; Mingfeng Liu; Einar Rosenqvist; E Arne Høiby; Daniel C Stein; Gary A Jarvis
Journal:  J Biol Chem       Date:  2015-12-11       Impact factor: 5.157

9.  Detection of gene expression in an individual cell type within a cell mixture using microarray analysis.

Authors:  Penelope A Bryant; Gordon K Smyth; Roy Robins-Browne; Nigel Curtis
Journal:  PLoS One       Date:  2009-02-12       Impact factor: 3.240

10.  Acyloxyacyl hydrolase modulates pelvic pain severity.

Authors:  Wenbin Yang; Ryan E Yaggie; Mingchen C Jiang; Charles N Rudick; Joseph Done; Charles J Heckman; John M Rosen; Anthony J Schaeffer; David J Klumpp
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-11-08       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.